Linked Life Data

759142

Source:http://linkedlifedata.com/resource/pubmed/id/759142

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1979-3-29
pubmed:abstractText
The efficacy and tolerance of Sandovac, a new subunit vaccine, was tested in 104 children and juveniles aged 2 1/4 to 17 years, at five children's clinics. Sandovac 1000 was given to 39 children, Sandovac 2000 to 65. The vaccine was well tolerated, no appreciable side effects--local or systemic--having been recorded. The efficacy of Sandovac was checked by determining the antibody titre against haemagglutinin and neuraminidase in 36 children before and 28 days after vaccination with SAndovac 1000. The conversion rate with haemagglutination-inhibiting antibody titres type A strain Victoria was 100% and type B strain Hong Kong 86%. The geometric mean values rose by a factor of 29 for type A and 7.4 for type B. For the neuraminidase-inhibiting antibodies the factors were 3.15 with type A and 5.83 with type B. Titre increases by a factor of at least 1.5 occurred in 75 and 84%, respectively of vaccinated children.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0012-0472
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
104
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
56-60
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1979
pubmed:articleTitle
[Immunisation against influenza with a new subunit vaccine tested on children at risk (author's transl)].
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Controlled Clinical Trial